Extended Data Fig. 7: Clinical correlation between KDM1B, type I interferon (IFN-I) signature, and stemness signature in breast cancer (BC) patients.

(a) Spearman correlations between expression scores of KDM1B and the reported IFN-I-related metagenes, stem-related reprogramming factors, IFN-I signatures and stemness signatures from microarray data of three publicly available cohorts of BC patients treated with neoadjuvant anthracycline-based chemotherapy. *P < 0.05, **P < 0.01, ***P < 0.001. (b) Kaplan–Meier plots depicting the distant relapse-free incidence (DRFI) in BC patients from the METABRIC cohort stratified according to risk behavior and boxplots reporting the expression levels of KDM1B and the illustrated stemness or IFN-I signatures. P value was calculated using the P Cox, Log-Rank (Mantel-Cox) test. P values <0.05 were considered statistically significant. The relative expression of the indicated genes and signatures is reported as mean ± s.e.m. from 1,903 patients. For statistics of boxplots see Supplementary Table 3. The correspondent disease-specific survival (DSS) is reported in Fig. 7b. (c,d) Analysis of the combined impact of KDM1B and the illustrated stemness and IFN-I signatures on DRFI and DSS on BC patients form the METABRIC database upon their stratification according positivity or negativity to the Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2, best known as HER2). P values are calculated as in (b). Ns, not-significant. (a) Two-sided Spearman’s rho.